Safety and immunogenicity of an adenoviral-vectored vaccine against Crimean–Congo haemorrhagic fever in the UK (CCHF01): an open-label, first-in-human, non-randomised, phase 1 clinical trial

The Lancet Infectious Diseases · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles